T. Rowe Price Investment Management’s AbbVie ABBV Stock Holding History

T. Rowe Price Investment Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.26M	Sell	5,805 -20,042	-78%	-$4.45M	﹤0.01%	615
2025 Q4	$5.91M	Buy	25,847 +7,116	+38%	+$1.62M	﹤0.01%	576
2025 Q3	$4.34M	Sell	18,731 -1,152,875	-98%	-$235M	﹤0.01%	578
2025 Q2	$217M	Buy	1,171,606 +12,357	+1%	+$2.3M	0.14%	169
2025 Q1	$243M	Buy	1,159,249 +1,153,249	+19,221%	+$224M	0.16%	147
2024 Q4	$1.07M	Sell	6,000 -4,661,205	-100%	-$857M	﹤0.01%	601
2024 Q3	$922M	Sell	4,667,205 -158,508	-3%	-$29.6M	0.56%	50
2024 Q2	$828M	Sell	4,825,713 -11,169	-0.2%	-$1.85M	0.52%	58
2024 Q1	$881M	Sell	4,836,882 -5,246	-0.1%	-$904K	0.54%	56
2023 Q4	$750M	Sell	4,842,128 -1,409,077	-23%	-$205M	0.49%	59
2023 Q3	$932M	Buy	6,251,205 +253,644	+4%	+$37.2M	0.66%	37
2023 Q2	$808M	Sell	5,997,561 -1,599,942	-21%	-$235M	0.55%	47
2023 Q1	$1.21B	Buy	7,597,503 +4,317,571	+132%	+$660M	0.87%	29
2022 Q4	$530M	Buy	+3,279,932	New	+$503M	0.41%	74

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management's ABBV Position: Q1 2026 in Review

T. Rowe Price Investment Management reduced its AbbVie (ABBV) stake by 78% in Q1 2026, selling an estimated $4.45M and leaving 5,805 shares worth $1.26M. The position accounts for ﹤0.01% of the portfolio, ranked #615.

T. Rowe Price Investment Management first reported a position in ABBV in Q4 2022 and has held it in 14 quarters since. The position peaked at $1.21B in Q1 2023. 4,088 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

T. Rowe Price Investment Management held 5,805 shares of AbbVie worth $1.26M as of Q1 2026.
T. Rowe Price Investment Management sold 20,042 AbbVie shares in Q1 2026, an estimated $4.45M.
AbbVie made up ﹤0.01% of T. Rowe Price Investment Management's portfolio in Q1 2026, its #615 holding.
T. Rowe Price Investment Management first reported a position in AbbVie in Q4 2022 and has held it in 14 quarters since.
T. Rowe Price Investment Management's AbbVie position peaked at $1.21B in Q1 2023.
4,088 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q1 2026, filed 15 May 2026.